122 related articles for article (PubMed ID: 20085999)
1. New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients.
Martin-Carbonero L; Soriano V
J Antimicrob Chemother; 2010 Mar; 65(3):379-82. PubMed ID: 20085999
[TBL] [Abstract][Full Text] [Related]
2. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
3. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of chronic hepatitis B in HIV co-infected patients].
Massard J; Benhamou Y
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt 2):S20-4. PubMed ID: 18662606
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Ristig MB; Crippin J; Aberg JA; Powderly WG; Lisker-Melman M; Kessels L; Tebas P
J Infect Dis; 2002 Dec; 186(12):1844-7. PubMed ID: 12447773
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
Revill PA; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin SR; Dore GJ; Matthews GV; Thio CL; Locarnini SA
AIDS; 2007 Aug; 21(13):1701-10. PubMed ID: 17690567
[TBL] [Abstract][Full Text] [Related]
8. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
[TBL] [Abstract][Full Text] [Related]
9. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic hepatitis B in HIV co-infected patients.
Guan R
Med J Malaysia; 2005 Jul; 60 Suppl B():52-6. PubMed ID: 16108174
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus and HIV infection.
Martín-Carbonero L; Poveda E
Semin Liver Dis; 2012 May; 32(2):114-9. PubMed ID: 22760650
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
Hoff J; Bani-Sadr F; Gassin M; Raffi F
Clin Infect Dis; 2001 Mar; 32(6):963-9. PubMed ID: 11247719
[TBL] [Abstract][Full Text] [Related]
17. Special considerations and treatment of patients with HBV-HIV coinfection.
Dieterich DT
Antivir Ther; 2007; 12 Suppl 3():H43-51. PubMed ID: 18284182
[TBL] [Abstract][Full Text] [Related]
18. Strategies for managing coinfection with hepatitis B virus and HIV.
Sherman M
Cleve Clin J Med; 2009 May; 76 Suppl 3():S30-3. PubMed ID: 19465707
[TBL] [Abstract][Full Text] [Related]
19. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel.
Soriano V; Puoti M; Peters M; Benhamou Y; Sulkowski M; Zoulim F; Mauss S; Rockstroh J
AIDS; 2008 Jul; 22(12):1399-410. PubMed ID: 18614862
[TBL] [Abstract][Full Text] [Related]
20. Treatment algorithm for chronic hepatitis B in HIV-infected patients.
Benhamou Y
J Hepatol; 2006; 44(1 Suppl):S90-4. PubMed ID: 16352368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]